Nuvaxovid COVID-19 vaccine authorized in the United Kingdom as a booster to prevent coronavirus disease caused by severe acute respiratory syndrome in adults
Novavax, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has expanded the conditional marketing authorization (CMA)i for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a homologous and heterologous booster dose after the primary series of Nuvaxovid (six months) or of an mRNA or adenoviral vector vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults aged 18 and older
The MHRA decision was based on data from Novavax' Phase II trial conducted in the U.S. and Australia (1,283 participants), from a separate Phase II trial conducted in South Africa (4,404 participants), and from the U.K.-sponsored COV-BOOST trial (2,878 participants). As part of the Phase II trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after their primary two-dose vaccination series of Nuvaxovid.
The third dose produced increased immune responses against the original ancestral strain of SARS-CoV-2 comparable to or exceeding levels associated with protection in Phase III clinical trials. In the COV-BOOST trial, Nuvaxovid increased antibody titers when used as a heterologous third booster dose after a primary two-dose vaccination series of an mRNA vaccine or adenoviral vector vaccine.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins